BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31371807)

  • 41. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
    Hwang HC; Pyott S; Rodriguez S; Cindric A; Carr A; Michelsen C; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 May; 40(5):714-8. PubMed ID: 26900815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
    Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
    J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.
    Vivero M; Bueno R; Chirieac LR
    Mod Pathol; 2018 Jan; 31(1):122-131. PubMed ID: 28884745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.
    De Rienzo A; Chirieac LR; Hung YP; Severson DT; Freyaldenhoven S; Gustafson CE; Dao NT; Meyerovitz CV; Oster ME; Jensen RV; Yeap BY; Bueno R; Richards WG
    J Pathol; 2021 Jan; 253(1):68-79. PubMed ID: 32944962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
    Febres-Aldana CA; Chang JC; Jungbluth AA; Adusumilli PS; Bodd FM; Frosina D; Geronimo JA; Hernandez E; Irawan H; Offin MD; Rekhtman N; Travis WD; Vanderbilt C; Zauderer MG; Zhang Y; Ladanyi M; Yang SR; Sauter JL
    Mod Pathol; 2024 Mar; 37(3):100420. PubMed ID: 38185249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
    Galateau-Salle F; Churg A; Roggli V; Travis WD;
    J Thorac Oncol; 2016 Feb; 11(2):142-54. PubMed ID: 26811225
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BAP1 protein is a progression factor in malignant pleural mesothelioma.
    Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
    Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Germline BAP1 mutations predispose to malignant mesothelioma.
    Testa JR; Cheung M; Pei J; Below JE; Tan Y; Sementino E; Cox NJ; Dogan AU; Pass HI; Trusa S; Hesdorffer M; Nasu M; Powers A; Rivera Z; Comertpay S; Tanji M; Gaudino G; Yang H; Carbone M
    Nat Genet; 2011 Aug; 43(10):1022-5. PubMed ID: 21874000
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
    Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
    Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
    Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
    Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
    Hung YP; Chirieac LR
    Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pleural mesothelioma classification update.
    Beasley MB; Galateau-Salle F; Dacic S
    Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genomic landscape of pleural and peritoneal mesothelioma tumours.
    Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A
    Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
    Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
    J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
    Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
    JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular characterization of pleomorphic mesothelioma: a multi-institutional study.
    Roy S; Galateau-Sallé F; Le Stang N; Churg A; Lyons MA; Attanoos R; Dacic S
    Mod Pathol; 2022 Jan; 35(1):82-86. PubMed ID: 34531524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
    Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
    JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
    Bott M; Brevet M; Taylor BS; Shimizu S; Ito T; Wang L; Creaney J; Lake RA; Zakowski MF; Reva B; Sander C; Delsite R; Powell S; Zhou Q; Shen R; Olshen A; Rusch V; Ladanyi M
    Nat Genet; 2011 Jun; 43(7):668-72. PubMed ID: 21642991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.